R-CHOP is a combination of five drugs that work together to target and kill cancer cells. It’s a first-line treatment for aggressive non-Hodgkin’s lymphoma, a group of blood cancers. Most often, ...
Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...
Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...
Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers The medians were not ...
A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...
Potato chop or aloo-r chop is a quintessential part of the telebhaja culture of Kolkata. By the term "telebhaja", we mean "fried in oil", and that's exactly what these represent. Most of the times, ...
Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...
Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish the maximum tolerated dose of ...
The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with ...
To participate in this study, patients were required to have a diagnosis of de novo DLBCL; be treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) with or without ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results